Your Messages Inbox (38) 
Your Unread Messages
See All
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Update on the Management of Pain in Arthritis and the Use of Cyclooxygenase-2 Inhibitors
Current Pain and Headache Reports, 11/06/09
Ross E – Chronic pain from arthritis continues to be one of the biggest causes of disability and loss of function in the United States today. This is still the case despite many new insights into the pathophysiology of pain, effective treatment approaches, and new, safer medications that can be used long–term. There are many different types of arthritic problems. New disease–modifying agents that are available for some of these types of arthritic diseases, such as rheumatoid arthritis, have the potential to have a substantial impact on improvement in the long–term prognosis. Despite this optimistic outlook, pain often is a significant problem and should be treated whenever it becomes a barrier to function. To complicate treatment for this condition, the most widely used group of medications is under new scrutiny because of concerns regarding long–term detrimental side effects. A complete understanding of the risk factors for NSAIDs, specifically cyclooxygenase–2 inhibitors, is still not available. But published data and new clinical guidelines still suggest that treatment for this large category of diseases can be effective and safe.
Today in Pain Management...keeping you current
Receive free subspecialty "5-minute updates" via email
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09
Use of oral ketamine in chronic pain management: A review
European Journal of Pain, 11/02/09
Ketoprofen 2% Oral Gel
U.S. Pharmacist, 11/06/09
Sponsor
Article Search
Sponsor